Added to YB: 2025-04-01
Pitch date: 2025-03-30
IGMS [neutral]
IGM Biosciences, Inc.
+6.72%
current return
Author Info
Enterprising Investor shares analysis of value stocks. Sign up for the newsletter.
Company Info
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
Market Cap
$76.6M
Pitch Price
$1.19
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.57
P/E
-1.44
EV/Sales
-0.19
Sector
Biotechnology
Category
special_situation
Having Fun with Special Situations - IGM Biosciences, Inc.
IGMS (liquidation): Biotech co suspends drug research, stock -80%. $183M cash/investments end 2024. 73% workforce cut to reduce burn. Thesis: liquidation for modest gain. Bought at $1.67, dropped to $1.20. $97M market cap at purchase. R&D spend $160M in 2024, now zero. SG&A $50M to decrease. Awaiting restructuring updates.
Read full article (1 min)